Home › Compare › MITUY vs ABBV
MITUY yields 4.24% · ABBV yields 3.12%● Live data
📍 MITUY pulled ahead of the other in Year 2
Combined, MITUY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MITUY + ABBV for your $10,000?
Mitsui Chemicals, Inc. engages in the mobility, health care, food and packaging, basic materials, and other businesses. The company's Mobility segment develops elastomers, performance compounds, functional polymers, polypropylene compounds, and performance polymers; and offers services related to the development of automotive and industrial products. Its Health Care segment offers vision care materials, nonwoven fabrics, dental materials, and personal care materials. The Food & Packaging segment provides coating and engineering materials, performance films and sheets, and agrochemical products. The Basic Materials segment provides ethylene, propylene, polyethylene, polypropylene, catalysts, phenols, purified terephthalic acid, PET, polyurethane materials, and industrial chemical products. The company also offers civil engineering and construction materials; cosmetics; wood adhesives, paper resins, foliar activator, and other chemical products; polyolefin, urethanes, and synthetic resins and resin films; injection molds and presses; phosphoric acid and fertilizers; spunbonded nonwoven fabrics and synthetic fibers; monomers for optical lenses; and fine chemical products and inorganic chemicals. In addition, it is involved in performance analysis, physical property measurements, and safety tests on chemicals; and placements, temporary works, and insurance and travel services, and consignments, as well as the sale of electronics and information materials. The company sells its products in Japan, China, Asia, the Americas, Europe, and internationally. Mitsui Chemicals, Inc. was founded in 1892 and is headquartered in Tokyo, Japan.
Full MITUY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.